Liven Pharma Limited has released its condensed interim financial statements for the first quarter of the financial year 2027, covering the three-month period ended September 30, 2026. The company’s latest quarterly report highlights its financial performance, operational challenges, corporate governance initiatives and strategic priorities as it continues to strengthen its position in Pakistan’s pharmaceutical industry.
Headquartered on Lahore Multan Road, Liven Pharma is engaged in the manufacturing and sale of pharmaceutical products. The company aims to provide high-quality, reliable and affordable healthcare solutions while expanding its business operations and pursuing opportunities in the domestic and international markets.
Financial Performance During the First Quarter
According to the company’s quarterly report, Liven Pharma recorded revenue of Rs. 14.29 million during the three months ended September 30, 2026. However, the company faced profitability challenges, reporting a gross loss of Rs. 2.57 million.
Administrative, selling and other operating expenses remained elevated during the reporting period, contributing to an operating loss of Rs. 17.51 million. After accounting for finance costs and taxation, the company reported a net loss after tax of Rs. 7.37 million.
The loss per share, both basic and diluted, stood at Rs. 0.07 compared with Rs. 0.28 in the corresponding period of the previous year. This represents an improvement in the reported per-share loss, although the company continues to face challenges in achieving profitability.
The board of directors has emphasized maintaining operational discipline, controlling expenses and improving efficiency while responding to prevailing market conditions.
Pharmaceutical Industry Outlook in Pakistan
Pakistan’s pharmaceutical industry continued to demonstrate resilience during the quarter, supported by consistent demand for essential medicines and healthcare products.
However, pharmaceutical manufacturers continue to face several operational challenges, particularly regulatory pricing controls and dependence on imported raw materials. Currency fluctuations, supply chain disruptions and changing cost structures can affect manufacturing expenses and profit margins.
Liven Pharma has stated that it is addressing these challenges through careful operational planning and continued engagement with relevant regulatory authorities.
Focus on Manufacturing and Product Quality
Product quality remains an important part of Liven Pharma’s business strategy. The company emphasizes sourcing raw materials, excipients and packaging materials from reputable manufacturers with appropriate certifications.
Its manufacturing operations cover different pharmaceutical product categories, including tablets, capsules, syrups, injectable general medicines, injectable psychotropic products and infusion vials.
The company aims to differentiate itself through reliable products, quality standards and affordable healthcare solutions rather than relying primarily on incentive-based marketing strategies.
Corporate Governance and Management Oversight
Liven Pharma continues to emphasize corporate governance, financial transparency and effective management oversight.
The company’s board includes independent, executive and non-executive directors. Its committees include the Audit Committee and Human Resource and Remuneration Committee, which oversee financial reporting, internal controls, employee policies and remuneration matters.
During the reporting quarter, the Audit Committee held one meeting to review matters relating to financial reporting and governance.
The company also highlighted its commitment to diversity, equity and inclusion, workplace safety and maintaining appropriate internal financial controls.
Corporate Social Responsibility Initiatives
Beyond its commercial activities, Liven Pharma has outlined its commitment to community development and social responsibility.
Its initiatives focus on communities surrounding its manufacturing facility, particularly in the areas of education, healthcare, livelihood opportunities and vocational training.
The company also reports providing free medical services to people in need near its facility. These activities reflect its stated objective of contributing to community welfare alongside its pharmaceutical manufacturing operations.
Future Prospects and Business Strategy
Looking ahead, Liven Pharma’s management remains cautiously optimistic about the company’s future prospects. Its priorities include improving operational efficiency, controlling expenses and pursuing sustainable business growth.
The company has also highlighted an ambition to strengthen its business platform, expand high-value ventures and pursue international growth opportunities.
Achieving these objectives will depend on its ability to manage manufacturing costs, improve gross margins, maintain product quality and navigate regulatory and economic challenges.
The board believes that continued operational improvements and effective risk management will help the company respond to emerging market opportunities.
Conclusion
Liven Pharma Limited’s first-quarter FY2027 results reflect a challenging financial period, with revenue of Rs. 14.29 million and a net loss of Rs. 7.37 million. Although profitability remains an important challenge, the improvement in loss per share compared with the previous year’s corresponding quarter provides a positive development in the reported financial indicators.
The company’s focus on product quality, cost management, corporate governance and business expansion will remain important as it works toward strengthening its market position.
Investors and industry observers will be watching future quarterly results to assess whether Liven Pharma can translate its strategic priorities into improved financial performance and sustainable profitability.
